Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
$0.21
$0.31
$0.19
$2.98
$2.28M2.67366,359 shs78,272 shs
Emerald Bioscience Inc. stock logo
EMBI
Emerald Bioscience
$10.17
$0.02
$0.20
$24.13M0.4314.24 million shs6.96 million shs
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
$0.45
$0.60
$0.42
$2.40
$3.76M0.2254,258 shs9,013 shs
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
+1.90%+4.65%-43.39%-54.49%-87.98%
Emerald Bioscience Inc. stock logo
EMBI
Emerald Bioscience
0.00%0.00%-99.25%-96.17%+556.93%
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
+0.90%-18.49%-24.15%-30.83%-76.93%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Emerald Bioscience Inc. stock logo
EMBI
Emerald Bioscience
N/AN/AN/AN/AN/AN/AN/AN/A
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
N/AN/AN/AN/A
Emerald Bioscience Inc. stock logo
EMBI
Emerald Bioscience
N/AN/AN/AN/A
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
N/AN/AN/AN/A($0.71) per shareN/A
Emerald Bioscience Inc. stock logo
EMBI
Emerald Bioscience
N/AN/AN/A1.20N/AN/A
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
$5.18M0.73N/AN/A($0.77) per share-0.58

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
-$18.85M-$5.66N/AN/AN/A-603.40%-421.35%5/20/2024 (Estimated)
Emerald Bioscience Inc. stock logo
EMBI
Emerald Bioscience
$1.05M-$0.08N/AN/AN/AN/AN/A-347.62%N/A
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
-$7.79M-$2.33N/AN/A-150.43%-517.99%-91.83%5/20/2024 (Estimated)

Latest CNSP, EVOK, and EMBI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/14/2024Q4 2023
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
N/A-$0.59-$0.59-$0.59N/A$1.68 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
N/AN/AN/AN/AN/A
Emerald Bioscience Inc. stock logo
EMBI
Emerald Bioscience
N/AN/AN/AN/AN/A
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
N/A
0.26
0.26
Emerald Bioscience Inc. stock logo
EMBI
Emerald Bioscience
0.43
3.59
3.59
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
N/A
2.25
2.09

Ownership

Institutional Ownership

CompanyInstitutional Ownership
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
14.02%
Emerald Bioscience Inc. stock logo
EMBI
Emerald Bioscience
5.58%
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
N/A

Insider Ownership

CompanyInsider Ownership
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
3.88%
Emerald Bioscience Inc. stock logo
EMBI
Emerald Bioscience
1.60%
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
11.78%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
310.64 million10.22 millionNot Optionable
Emerald Bioscience Inc. stock logo
EMBI
Emerald Bioscience
4268.07 millionN/ANot Optionable
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
48.48 million7.48 millionNot Optionable

CNSP, EVOK, and EMBI Headlines

SourceHeadline
Like a homecoming: Inizio Evoke Comms welcomes back alum DeViteri as North American president'Like a homecoming': Inizio Evoke Comms welcomes back alum DeViteri as North American president
fiercepharma.com - April 23 at 9:26 AM
Evoke Pharma (NASDAQ:EVOK) Stock Crosses Below 200 Day Moving Average of $0.93Evoke Pharma (NASDAQ:EVOK) Stock Crosses Below 200 Day Moving Average of $0.93
americanbankingnews.com - April 18 at 3:26 AM
Evoke Pharma (NASDAQ:EVOK) Coverage Initiated at StockNews.comEvoke Pharma (NASDAQ:EVOK) Coverage Initiated at StockNews.com
americanbankingnews.com - April 18 at 2:30 AM
Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 MedicationsEvoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications
finance.yahoo.com - April 17 at 10:11 AM
Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 MedicationsEvoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications
globenewswire.com - April 17 at 8:30 AM
DelveInsight Business Research, LLP: Gastroparesis Market to Witness Upsurge in Growth at a CAGR of 7% by 2034 | DelveInsightDelveInsight Business Research, LLP: Gastroparesis Market to Witness Upsurge in Growth at a CAGR of 7% by 2034 | DelveInsight
finanznachrichten.de - April 10 at 7:22 PM
Empowering students: Innovative approaches to climate change educationEmpowering students: Innovative approaches to climate change education
msn.com - April 10 at 9:21 AM
Stephanie Carman Joins Underscore Marketing as SVP Client Services; Tiffany Marg Joins Strategy TeamStephanie Carman Joins Underscore Marketing as SVP Client Services; Tiffany Marg Joins Strategy Team
finance.yahoo.com - April 10 at 9:21 AM
How a Dubai man built a $200,000 art collection in his Business Bay homeHow a Dubai man built a $200,000 art collection in his Business Bay home
msn.com - April 1 at 9:18 PM
The Secret Behind Your Soda: The Cocaine-Free Journey of Coca Leaves in Coca-ColaThe Secret Behind Your Soda: The Cocaine-Free Journey of Coca Leaves in Coca-Cola
msn.com - March 30 at 10:47 PM
Brain-Triggered Snacking: A New Understanding of Eating Impulses : ScienceAlertBrain-Triggered Snacking: A New Understanding of Eating Impulses : ScienceAlert
msn.com - March 30 at 7:37 AM
Evoke Pharma, Inc.: Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. DOnofrio to Chief Executive OfficerEvoke Pharma, Inc.: Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D'Onofrio to Chief Executive Officer
finanznachrichten.de - March 22 at 8:55 AM
Evoke Pharma Taps Operating Chief DOnofrio to Succeed CEO GonyerEvoke Pharma Taps Operating Chief D'Onofrio to Succeed CEO Gonyer
marketwatch.com - March 21 at 5:34 PM
Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D’Onofrio to Chief Executive OfficerEvoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D’Onofrio to Chief Executive Officer
finance.yahoo.com - March 21 at 5:34 PM
Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. DOnofrio to Chief Executive OfficerEvoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D'Onofrio to Chief Executive Officer
globenewswire.com - March 21 at 4:15 PM
‘Saving animals is ethical, it’s evocative. And it’s smart business’‘Saving animals is ethical, it’s evocative. And it’s smart business’
timesofindia.indiatimes.com - March 19 at 1:56 AM
Big change is the only constant in eco: India IncBig change is the only constant in eco: India Inc
msn.com - March 18 at 10:54 AM
BU study reveals key to combating high-risk neuroblastomaBU study reveals key to combating high-risk neuroblastoma
news-medical.net - March 17 at 8:08 PM
Evoke Pharma, Inc. (EVOK) Q4 2023 Earnings Call TranscriptEvoke Pharma, Inc. (EVOK) Q4 2023 Earnings Call Transcript
seekingalpha.com - March 17 at 12:09 AM
Evoke Pharma, Inc. (NASDAQ:EVOK): Are Analysts Optimistic?Evoke Pharma, Inc. (NASDAQ:EVOK): Are Analysts Optimistic?
finance.yahoo.com - March 16 at 2:08 PM
Brain gain: Hope rises with new dementia treatmentsBrain gain: Hope rises with new dementia treatments
msn.com - March 15 at 9:08 PM
Evoke Pharma, Inc. (NASDAQ:EVOK) Q4 2023 Earnings Call TranscriptEvoke Pharma, Inc. (NASDAQ:EVOK) Q4 2023 Earnings Call Transcript
finance.yahoo.com - March 15 at 4:06 PM
Evoke Pharma, Inc.: Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial ResultsEvoke Pharma, Inc.: Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results
finanznachrichten.de - March 15 at 11:04 AM
EVOK Stock Earnings: Evoke Pharma Misses EPS, Beats Revenue for Q4 2023EVOK Stock Earnings: Evoke Pharma Misses EPS, Beats Revenue for Q4 2023
msn.com - March 15 at 11:04 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

CNS Pharmaceuticals logo

CNS Pharmaceuticals

NASDAQ:CNSP
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.
Emerald Bioscience logo

Emerald Bioscience

OTCMKTS:EMBI
Emerald Bioscience, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics for unmet medical needs worldwide. The company's lead product candidate is NB1111, which is in preclinical trials for the treatment of glaucoma. It is also developing NB2222, a product candidate in preclinical trials for use in the treatment of various eye diseases, including uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy; and NB3111, a cannabinoid cocktail in testing for use as an anti-infective agent against various strains of antibiotic resistant bacteria, including methicillin-resistant Staphylococcus aureus. The company was formerly known as Nemus Bioscience, Inc. and changed its name to Emerald Bioscience, Inc. in March 2019. Emerald Bioscience, Inc. was founded in 2012 and is based in San Diego, California.
Evoke Pharma logo

Evoke Pharma

NASDAQ:EVOK
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.